Funding for this research was provided by:
National Institute on Drug Abuse (T32DA013911, R25DA037190)
National Institute of Allergy and Infectious Diseases (T32-AI052074)
Article History
Received: 21 June 2022
Accepted: 12 December 2022
First Online: 3 January 2023
Declarations
:
: Dr. LaRochelle received consulting funds for research on opioid use disorder treatment pathways paid to his institution from OptumLabs, which was not related to this study. Drs. Bovell-Ammon and Fox have no potential or actual conflicts of interest to disclose.
Free to read: This content has been made available to all.